Eli Lilly and Company ($LLY) is experiencing notable market fluctuations following the release of a new guide, which has reportedly impacted its stock price. On January 14, 2025, $LLY shares fell by 4%, while its competitor, Vaxart ($VKTX), saw a decline of 6.5%. The overall health care sector, represented by the Health Care Select Sector SPDR Fund ($XLV), is also feeling the effects of Lilly's performance. Analysts have pointed out that $VKTX is facing challenges due to the lack of a partnership announcement during the JPMorgan Healthcare Conference, contributing to its 10% drop on the same day and a 65% decline from its all-time high. Despite these setbacks, some traders are optimistic about potential gains, with one noting a substantial profit of 500% from a recent trade involving $LLY. The market's reaction to these developments highlights the volatility within the biotech sector, particularly in relation to GLP-1 treatments.